UK: What Would Brexit Mean For The Pharma Industry?

Last Updated: 17 February 2016
Article by Karen Taylor

Most Read Contributor in UK, August 2017

The Conservatives' 2015 election manifesto committed to hold a referendum by 2017 on whether or not the UK should stay in or leave the European Union. Increasing unrest among Eurosceptic politicians and a narrowing of the polls on the likely outcome of the vote has led to the suggestion that the referendum could be held as early as June or September 2016. While all industries are speculating on the potential impact of an "out" vote, the global pharmaceutical industry faces some very specific concerns. This blog considers some of the main questions that the pharmaceutical industry is contemplating as part of the in/out debate.

Investment and research funding

The UK has a strong history of research and commercial science, having pioneered many scientific breakthroughs and driven scientific collaboration worldwide. It is the headquarters for some major European organisations, such as the European Medicines Agency, and is enjoys a strong and productive life sciences sector, underpinned by a university sector that has the strongest global university rankings in Europe. Membership of the EU has been important in attracting investment into domestic life science capabilities. Brexit is likely to result in the following risks to such investments:

  • If global pharmaceutical companies invest in the UK they will have access to the EU market which may not be the case in the event of a Brexit. For many investment decisions unrestricted access to the EU market is important. Brexit risks removing this incentive
  • the UK receives more funding from the European Research Council than any other EU country supporting universities project based research. One government minister has told Parliament's Science and Technology Committee that Brexit could threaten £8.5 billion of EU funding for UK science over the next four years1. There is also a risk that UK researchers will lose their priority access to scientific facilities across Europe2
  • a wide range of EU public/private partnerships exist, such as the Innovative Medicines Initiative (IMI), which supports collaborative research projects and helps build up networks of industry and academic experts to boost pharmaceutical innovation in the EU. With half of the funding for the IMI coming from the EU, the advantages lie not just in the money but in the ability to bring together companies and researchers from different EU countries to share knowledge and experience. Domestic research investment is likely to suffer if the UK was no longer part of this initiative.

Regulation and clinical trials processes

Currently the European Medicines Agency (EMA) can grant pharmaceutical companies a single marketing authorisation, providing faster access to the whole of the EU market - half a billion potential patients.iii  The level of disruption following a Brexit would depend on whether the UK remained part of the European regulatory framework. If not, the UK will have to resume separate authorisations and inspections leading to duplication and delay. It's also clear that the EMA would relocate its UK headquarters to another country within the EU in the event of Brexit, this could interrupt drugs currently under regulatory review.  However, if the vote was to leave the EU, it could still be possible to remain under the EMA's umbrella, as demonstrated by Norway and Iceland, a move that could be seen as mutually beneficial.

Talent

There are also additional risks to the pharmaceutical labour force. Brexit could isolate the country's scientists and reduce its influence in medicine. Most research and development facilities in the UK are staffed by people from across the EU; meaning pharmaceutical companies may find it more difficult to attract talent from abroad and retain existing talent. For example, if EU funding was cut to UK research projects, how quickly might academics desert the UK for countries with easier access to collaborative international research projects? There are also questions as to whether UK scientists, or pharmaceutical executives, would enjoy the same rights they do now to work in any EU country, or would they become subject to new residence, visa and work permit controls?

Access

The UK plays an important role in initiatives like early-access programmes, adaptive pathways and international collaboration on health technology assessments etcetera. Brexit could jeopardize UK participation in pan-European projects intended to speed up patient access to innovation.

Brexit could also impact domestic drug access. Pharmaceutical companies think carefully about their launch sequences and an EU exit could see the UK slip down the priority list if companies have to jump through extra hoops to win approval there. The UK's approach to market access and approach to pricing could compound the situation, making the UK a less attractive launch market and reducing patient access to innovative medicines.

While recent weeks have seen an increase in reactions to the Brexit debate, many parties, including pharmaceutical trade bodies, appear to be keeping their powder dry. Indeed it's difficult for anyone to predict accurately what a post-Brexit world will look like. For many in the UK, the debate seems similar to that seen during the recent Scottish independence referendum and, as yet, decision time feels seems some way off, with current debate dominated by factors such as immigration and the migrant crisis rather than the impact on industrial competitiveness.

There is much uncertainty surrounding Brexit, but what does seem clear is that there will be complex consequences for the pharmaceutical industry. Among the many nuances that will become clearer, as the time to decide gets closer, is the fact that it is more than simply an in/out vote. Even if the referendum yields an 'out' vote, the UK would still have to negotiate its relationship with the EU. The status of its relationship with the EU would be subject to the agreement of remaining EU members, options could include remaining part of the European Economic Area (EEA), joining the European Free Trade Association, which allows participation in the EU single market or a more remote trade relationship. While Eurosceptics point to the success of Switzerland's pharmaceuticals industry (the biggest in Europe by market capitalisation) as evidence that life outside the EU is compatible with a thriving life-sciences sector it remains uncertain whether European governments will grant the UK similar privileges.

Footnotes

1 http://www.ft.com/cms/s/0/9216298e-bf67-11e5-846f-79b0e3d20eaf.html#axzz3zr7WOYXF

2 http://www.nature.com/news/academics-across-europe-join-brexit-debate-1.19282

3 http://uk.reuters.com/article/us-britain-eu-medicines-idUKKCN0V71AS

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.